DCF Advisers LLC Has $1.49 Million Stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

DCF Advisers LLC lifted its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 2.1% during the second quarter, Holdings Channel reports. The fund owned 290,684 shares of the company’s stock after acquiring an additional 6,000 shares during the quarter. DCF Advisers LLC’s holdings in Lifecore Biomedical were worth $1,491,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new position in shares of Lifecore Biomedical in the second quarter valued at approximately $56,000. Allegheny Financial Group LTD acquired a new position in Lifecore Biomedical in the 2nd quarter valued at $52,000. Rhumbline Advisers raised its holdings in Lifecore Biomedical by 1,668.5% in the 2nd quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock worth $138,000 after acquiring an additional 25,378 shares during the period. Bank of New York Mellon Corp bought a new position in Lifecore Biomedical in the 2nd quarter worth $327,000. Finally, Boston Partners acquired a new position in Lifecore Biomedical during the 1st quarter worth $104,000. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LFCR has been the topic of several research analyst reports. Craig Hallum initiated coverage on Lifecore Biomedical in a research report on Thursday, September 5th. They issued a “buy” rating and a $8.00 price target on the stock. Barrington Research lowered Lifecore Biomedical from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 28th.

Lifecore Biomedical Trading Up 8.1 %

Shares of LFCR stock opened at $5.62 on Friday. The firm has a market capitalization of $170.41 million, a P/E ratio of -1.68 and a beta of 0.95. Lifecore Biomedical, Inc. has a 1 year low of $3.68 and a 1 year high of $8.90. The firm’s fifty day simple moving average is $5.29 and its 200 day simple moving average is $5.74. The company has a current ratio of 2.08, a quick ratio of 1.06 and a debt-to-equity ratio of 12.90.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Monday, August 26th. The company reported ($0.15) earnings per share (EPS) for the quarter. Lifecore Biomedical had a negative return on equity of 515.12% and a net margin of 9.37%. The company had revenue of $37.89 million for the quarter. As a group, sell-side analysts predict that Lifecore Biomedical, Inc. will post -0.89 EPS for the current year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.